Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer
Theralase Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF) has announced that its lead drug formulation, Rutherrin, significantly enhances the efficacy of Cisplatin in chemotherapy-resistant Non-Small Cell Lung Cancer (NSCLC). In a preclinical study using the Lewis Lung Cancer (LLC1) orthotopic model, mice treated with a combination of Cisplatin and Rutherrin showed a significantly higher survival rate (p<0.001) compared to those treated with Cisplatin alone or untreated.
This breakthrough could potentially address the issue of chemotherapy drug resistance in cancer treatment. Theralase plans to commence clinical studies for brain cancer, lung cancer, and various blood-based cancers in 2025, pending sufficient capitalization and completion of Good Laboratory Practice toxicology analysis for Rutherrin.
Theralase Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF) ha annunciato che la sua formulazione di farmaco principale, Rutherrin, migliora significativamente l'efficacia del Cisplatino nel trattamento del Cancro Polmonare Non a Piccole Cellule (NSCLC) resistente alla chemioterapia. In uno studio preclinico utilizzando il modello ortotopico di Cancro Polmonare Lewis (LLC1), i topi trattati con una combinazione di Cisplatino e Rutherrin hanno mostrato un tasso di sopravvivenza significativamente più elevato (p<0.001) rispetto a quelli trattati solo con Cisplatino o non trattati.
Questa scoperta potrebbe affrontare il problema della resistenza ai farmaci chemioterapici nel trattamento del cancro. Theralase prevede di avviare studi clinici per il cancro al cervello, il cancro ai polmoni e vari cancri del sangue nel 2025, soggetti a sufficiente capitalizzazione e al completamento dell'analisi di tossicologia secondo le Buone Pratiche di Laboratorio per Rutherrin.
Theralase Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF) ha anunciado que su formulación de fármaco líder, Rutherrin, mejora significativamente la eficacia del Cisplatino en el cáncer de pulmón no microcítico (NSCLC) resistente a la quimioterapia. En un estudio preclínico utilizando el modelo ortotópico de cáncer de pulmón Lewis (LLC1), los ratones tratados con una combinación de Cisplatino y Rutherrin mostraron una tasa de supervivencia significativamente más alta (p<0.001) en comparación con aquellos tratados solo con Cisplatino o no tratados.
Este avance podría abordar el problema de la resistencia a los fármacos de quimioterapia en el tratamiento del cáncer. Theralase planea iniciar estudios clínicos para el cáncer de cerebro, cáncer de pulmón y varios cánceres de sangre en 2025, sujeto a suficiente capitalización y a la finalización del análisis de toxicología de Buenas Prácticas de Laboratorio para Rutherrin.
Theralase Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF)는 자사의 주요 약물 조제물인 Rutherrin이 화학 요법 내성 비소세포 폐암(NSCLC)에서 Cisplatin의 효능을 크게 향상시킨다고 발표했습니다. 루이스 폐암(LLC1) 정위 모델을 사용한 전임상 연구에서는 Cisplatin과 Rutherrin의 조합으로 치료한 쥐들이 단독으로 Cisplatin으로 치료한 그룹이나 치료를 받지 않은 그룹에 비해 상당히 높은 생존율을 보였습니다 (p<0.001).
이 돌파구는 암 치료에서 화학 요법 약물의 내성 문제를 해결할 수 있는 가능성을 제시합니다. Theralase는 2025년까지 뇌암, 폐암 및 다양한 혈액암에 대한 임상 연구를 시작할 계획이며, 이는 충분한 자본과 Rutherrin에 대한 우수 실험실 관행 독성 분석이 완료되어야 가능합니다.
Theralase Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF) a annoncé que sa principale formulation médicamenteuse, Rutherrin, améliore considérablement l'efficacité du Cisplatine dans le cancer du poumon non à petites cellules (NSCLC) résistant à la chimiothérapie. Dans une étude préclinique utilisant le modèle orthotopique du cancer du poumon de Lewis (LLC1), les souris traitées avec une combinaison de Cisplatine et de Rutherrin ont montré un taux de survie significativement plus élevé (p<0.001) par rapport à celles traitées uniquement avec Cisplatine ou non traitées.
Cette avancée pourrait potentiellement résoudre le problème de la résistance aux médicaments de chimiothérapie dans le traitement du cancer. Theralase prévoit de commencer des études cliniques pour le cancer du cerveau, le cancer du poumon et divers cancers du sang en 2025, sous réserve d'un financement suffisant et de la finalisation de l'analyse de toxicologie selon les Bonnes Pratiques de Laboratoire pour Rutherrin.
Theralase Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF) hat angekündigt, dass seine Hauptmedikation Rutherrin die Wirksamkeit von Cisplatin bei chemotherapieresistentem nicht kleinzelligem Lungenkrebs (NSCLC) signifikant verbessert. In einer präklinischen Studie mit dem orthotopischen Modell des Lewis-Lungenkrebses (LLC1) zeigten Mäuse, die mit einer Kombination aus Cisplatin und Rutherrin behandelt wurden, eine deutlich höhere Überlebensrate (p<0.001) im Vergleich zu jenen, die nur mit Cisplatin oder unbehandelt waren.
Dieser Durchbruch könnte das Problem der Resistenz gegen Chemotherapiemedikamente in der Krebsbehandlung angehen. Theralase plant, 2025 klinische Studien für Gehirnkrebs, Lungenkrebs und verschiedene blutbasierte Krebsarten zu starten, vorbehaltlich ausreichender Kapitalisierung und dem Abschluss der toxikologischen Analyse gemäß den Guten Laborpraktiken für Rutherrin.
- Rutherrin significantly enhances Cisplatin efficacy in chemotherapy-resistant NSCLC
- Combination of Cisplatin and Rutherrin showed significantly higher survival rate (p<0.001) in preclinical study
- Potential to address chemotherapy drug resistance in cancer treatment
- Plans to commence clinical studies for multiple cancer types in 2025
- Clinical studies for Rutherrin are still pending and not yet commenced
- Commencement of clinical studies in 2025 is subject to sufficient capitalization
TORONTO, ON / ACCESSWIRE / August 28, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation and or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it's lead drug formulation, Rutherrin®, has demonstrated an ability to provide a significant enhancement of Cisplatin efficacy in chemotherapy resistant Non-Small Cell Lung Cancer ("NSCLC") in a preclinical animal model.
Theralase® recently press released its latest research, using the well-established Lewis Lung Cancer ("LLC1") orthotopic model, representing NSCLC. In this model, mouse lungs are implanted with lung cancer cells, inducing these mice to develop very aggressive, fast growing and metastatic lung tumors.
In further experimentation, mice were treated with Cisplatin (currently one of the most prescribed chemotherapy drugs for lung cancer) in a control group versus Cisplatin combined with Rutherrin® in an active group.
The mice treated with Cisplatin and Rutherrin® demonstrated a significantly higher (p<0.001) enhancement of cisplatin efficacy and a significantly higher (p < 0.001) increase in overall mouse survival. This survival is analogous to a 1 year overall survival in humans and is significant due to the aggressiveness of the LLCI orthotopic model.
As shown in Figure 1, the Kaplan-Meier Curve represents animal survival versus time in days. As can be seen, the combination of Cisplatin with Rutherrin® produced a highly significant increase in overall survival of mice treated versus those who were untreated or treated with Cisplatin only.
Theralase® believes that this preclinical data could be even further improved with the addition of radiation or Metformin to activate Rutherrin®, while resident in NSCLC cells.
Figure 1: Kaplan-Meier Curve Survival Analysis of Mice After Tumour Inoculation and Treatment with Cisplatin or a Combined Treatment of Rutherrin® and Cisplatin
Dr. Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer of Theralase® stated, "Cisplatin-based therapy is one of the most important and highly prescribed chemotherapy treatments for cancer; however, it's efficacy is severely limited by chemotherapy drug resistance, as over time its efficacy decreases. Therefore, it is of significant clinical importance to develop effective synergistic agents to aid in Cisplatin's efficacy. In the latest preclinical study, we have demonstrated the value of using Rutherrin®, as a synergistic agent. The combination of Rutherrin® and Cisplatin exhibited a significant synergistic anti-cancer efficacy and demonstrated significantly longer animal survival (p<0.001). Upon clinical development and commercialization, this preclinical data is very important to the clinical community in the treatment of their lung cancer patients, as it demonstrates how their patients, who do develop chemotherapy resistance, can be treated more effectively with a combination drug therapy, such as Cisplatin and Rutherrin®. These results also suggest an exciting new direction for Theralase® in future drug development to help overcome chemoresistance, which is one of the major clinical challenges in cancer therapy".
Roger DuMoulin-White, B.E.Sc., P.Eng., Pro.Dir., President and Chief Executive Officer of Theralase® stated, "This latest research is extremely important to the clinical community, as pending regulatory approval, it provides an opportunity on how to treat their patient base, who have developed chemotherapeutic resistance to Cisplatin. Pending sufficient capitalization and completion of a Good Laboratory Practice ("GLP") toxicology analysis for Rutherrin®, Theralase® plans to commence clinical studies for brain cancer, lung cancer and various blood-based cancers in 2025. If proven safe and effective in humans, Theralase® hopes to change the paradigm of how patients diagnosed with cancer are treated in the future."
About Cisplatin:
Many chemotherapeutic drugs have been explored and developed for clinical studies. Cisplatin is one of the most potent anti-cancer agents ever developed. It provides clinical effectiveness against a wide spectrum of solid cancers and has been in clinical use for many years; however, many kinds of cancer cells are immune to it or quickly become chemoresistant to it.
About Lung Cancer:
Lung cancer is the leading cause of cancer death worldwide. Most patients die of progressive metastatic disease despite aggressive local and systemic therapies. The survival rate for lung cancer depends on the type, stage and age of the patient, with the overall 5-year survival rate for all types of lung cancer to be about
About Theralase® Technologies Inc.:
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.
Additional information is available at www.theralase.com and www.sedar.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements:
This news release contains "forward-looking statements" within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. Forward looking statements may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of Company's management for future research, development and commercialization of the Company's small molecules and their drug formulations, preclinical research, clinical studies and regulatory approvals.
These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations, the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all, the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies, the risk that the Company's fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, the Company's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.
Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate as such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements.
Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.
All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements.
For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies.
For More Information:
1.866.THE.LASE (843-5273)
416.699.LASE (5273)
www.theralase.com
Kristina Hachey, CPA
Chief Financial Officer
X 224
khachey@theralase.com
SOURCE: Theralase Technologies, Inc.
View the original press release on accesswire.com
FAQ
What is the significance of Theralase's (TLTFF) Rutherrin in cancer treatment?
When does Theralase (TLTFF) plan to start clinical studies for Rutherrin?
What were the results of Theralase's (TLTFF) preclinical study with Rutherrin?
How does Rutherrin potentially improve cancer treatment according to Theralase (TLTFF)?
